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BACKGROUND
The effect of internal mammary and medial supraclavicular lymph-node irradiation 
(regional nodal irradiation) added to whole-breast or thoracic-wall irradiation after 
surgery on survival among women with early-stage breast cancer is unknown.
METHODS
We randomly assigned women who had a centrally or medially located primary 
tumor, irrespective of axillary involvement, or an externally located tumor with 
axillary involvement to undergo either whole-breast or thoracic-wall irradiation in 
addition to regional nodal irradiation (nodal-irradiation group) or whole-breast or 
thoracic-wall irradiation alone (control group). The primary end point was overall 
survival. Secondary end points were the rates of disease-free survival, survival free 
from distant disease, and death from breast cancer.
RESULTS
Between 1996 and 2004, a total of 4004 patients underwent randomization. The 
majority of patients (76.1%) underwent breast-conserving surgery. After mastec-
tomy, 73.4% of the patients in both groups underwent chest-wall irradiation. 
Nearly all patients with node-positive disease (99.0%) and 66.3% of patients with 
node-negative disease received adjuvant systemic treatment. At a median follow-up 
of 10.9 years, 811 patients had died. At 10 years, overall survival was 82.3% in the 
nodal-irradiation group and 80.7% in the control group (hazard ratio for death 
with nodal irradiation, 0.87; 95% confidence interval [CI], 0.76 to 1.00; P = 0.06). 
The rate of disease-free survival was 72.1% in the nodal-irradiation group and 
69.1% in the control group (hazard ratio for disease progression or death, 0.89; 
95% CI, 0.80 to 1.00; P = 0.04), the rate of distant disease-free survival was 78.0% 
versus 75.0% (hazard ratio, 0.86; 95% CI, 0.76 to 0.98; P = 0.02), and breast-cancer 
mortality was 12.5% versus 14.4% (hazard ratio, 0.82; 95% CI, 0.70 to 0.97; 
P = 0.02). Acute side effects of regional nodal irradiation were modest.
CONCLUSIONS
In patients with early-stage breast cancer, irradiation of the regional nodes had a 
marginal effect on overall survival. Disease-free survival and distant disease-free 
survival were improved, and breast-cancer mortality was reduced. (Funded by Fonds 
Cancer; ClinicalTrials.gov number, NCT00002851.)
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The first filter stations for the lymphatic drainage of the breast are the axillary and internal mammary lymph 
nodes.1 Surgical studies have shown that the 
incidence of metastatic involvement of the inter-
nal mammary nodes varies between 4% and 9% in 
patients with axillary node–negative breast can-
cer and between 16% and 65% in patients with 
axillary node–positive breast cancer.2-4 As a con-
sequence, surgical dissection of the internal 
mammary nodes was attempted but abandoned 
in the 1970s, since no improvement in survival 
was observed.4,5
Elective irradiation of the regional nodes re-
mained widely used until the late 1980s, when it 
became less popular on the basis of an overview 
of older trials that showed no survival benefit, 
despite improvement in control of locoregional 
disease.6 There was even a suggestion of de-
creased long-term survival owing to irradiation 
of the heart.5-7 However, some studies predicted 
a beneficial effect in patients who had a high 
risk of regional involvement.8,9 Because of this 
controversy, many centers irradiated only the 
axilla and medial supraclavicular nodes in pa-
tients with risk factors and avoided the internal 
mammary nodes to protect the heart.
A renewed interest in the role of elective irra-
diation of the regional lymph nodes emerged af-
ter publication of results of studies that showed 
a favorable effect of postmastectomy radiation 
therapy and after improvement in techniques 
that led to less cardiac exposure.10-13 Because of 
the uncertainties regarding the role of internal 
mammary irradiation, the Radiation Oncology 
and Breast Cancer Groups of the European Orga-
nization for Research and Treatment of Cancer 
(EORTC) initiated a randomized, multicenter, 
phase 3 trial (EORTC 22922/10925) to investigate 
the effect of elective internal mammary and me-
dial supraclavicular lymph-node irradiation (here 
termed regional nodal irradiation) on overall sur-
vival. Details about the study population, radia-
tion techniques, quality-assurance program, and 
toxic effects after 3 years of follow-up have been 
published previously.14-17 We report here the final 
analysis of the primary and secondary end points, 
after a median follow-up of 10.9 years. Long-
term analyses are planned after a median follow-
up of 15 and 20 years.
Me thods
Patients
From July 1996 through January 2004, a total of 
4004 patients were enrolled at 46 institutions in 
13 countries. Eligibility criteria included unilat-
eral histologically confirmed breast adenocar-
cinoma of stage I, II, or III with a centrally or 
medially located primary tumor, irrespective of 
axillary involvement, or an externally located 
tumor with axillary involvement. Eligible pa-
tients had undergone mastectomy or breast-
conserving surgery and axillary dissection. Dur-
ing the last years of the trial, patients were 
eligible if they had undergone a sentinel-node 
biopsy followed by an axillary dissection in the 
case of a positive node.
Study Design and Oversight
After written informed consent was obtained 
from all patients, randomization was performed 
centrally at the EORTC headquarters. Patients 
were assigned to undergo regional nodal irradia-
tion (at a dose of 50 Gy in 25 fractions) or no 
regional nodal irradiation. A minimization algo-
rithm for randomization in a 1:1 ratio was used 
to stratify group assignments according to insti-
tution, menopausal status, tumor site within the 
breast, type of breast surgery, type of axillary 
dissection, pathological tumor stage, and patho-
logical nodal stage.
During follow-up, patients were seen annu-
ally for the first 5 years and then every 2 years 
unless disease recurrence or death occurred. In 
addition to the patient’s performance status 
(according to the Eastern Cooperative Oncology 
Group scale), the presence of any clinical evi-
dence of lung or cardiac fibrosis, cardiac disease, 
and other late toxic effects (scored on the basis 
of the patient’s history and, if symptoms were 
present, on further examination) was scored. 
Annual chest radiography was recommended. 
Data on serious adverse events were not collect-
ed. Data collection and analysis were performed 
at the EORTC headquarters.
The study was designed by the authors, who 
vouch for the accuracy and completeness of the 
data and fidelity to the study protocol, which is 
available with the full text of this article at 
NEJM.org. No commercial support was provided 
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for this study, and no one who is not an author 
contributed to writing the manuscript.
End Points
The primary end point was overall survival. Sec-
ondary end points were the rates of disease-free 
survival, distant disease-free survival, and death 
from breast cancer.
Overall survival was calculated from the date 
of randomization to the date of death from any 
cause. Disease-free survival was calculated from 
the date of randomization to the first date of 
local recurrence, regional recurrence, distant re-
currence, second breast cancer, or death from 
any cause, whichever occurred first. Distant 
disease-free survival was calculated from the date 
of randomization to the first date of distant 
disease or death from any cause, whichever oc-
curred first. Death from breast cancer was cal-
culated from the date of randomization to the 
date of death from breast cancer; the other 
causes of death were considered to be competing 
risks. Time to any first recurrence of breast can-
cer was calculated from the date of randomiza-
tion to the first date of local recurrence, regional 
recurrence, distant disease, death from breast 
cancer, or a second ipsilateral breast cancer, 
whichever occurred first.
Contralateral breast cancer, a second cancer 
other than breast cancer, and death due to other 
causes were considered to be competing risks. 
For all end points, data on patients who had had 
no event at the cutoff date for the final analysis 
were censored at the date of the last follow-up.
Statistical Analysis
The trial was designed to detect a difference of 
4 percentage points (79% vs. 75%) in 10-year 
overall survival with whole-breast or thoracic-
wall irradiation in addition to regional nodal 
irradiation as compared with whole-breast or 
thoracic-wall irradiation alone (hazard ratio for 
death, 0.82). We estimated that 4000 patients 
would be needed for 791 deaths to occur, which 
would give the study 80% power at a two-sided 
significance level of 5% to detect a 4 percentage-
point difference, assessed by means of the log-
rank test. Time-to-event curves were estimated 
by the Kaplan–Meier method and compared with 
the use of a two-sided log-rank test. The cumu-
lative incidences of death from breast cancer and 
the first recurrence of breast cancer were com-
pared by means of the Fine–Gray test.
Exploratory analyses were performed to test 
the heterogeneity of treatment effect for overall 
and disease-free survival across prespecified sub-
groups defined according to the stratification 
factors, and forest plots were used to present the 
results. Data on all patients who underwent 
randomization were analyzed according to the 
intention-to-treat principle. Analyses were per-
formed with the use of SAS software, version 9.4 
(SAS Institute).
R esult s
Patient and Tumor Characteristics
Of the 4004 patients who underwent randomiza-
tion, 32 (0.8%) were clinically ineligible, mainly 
because of concurrent disease or a tumor stage 
that did not meet the eligibility criteria. An-
other 106 patients (2.6%) were not treated ac-
cording to the protocol (Fig. 1). The character-
istics of the patients were similar in the two 
study groups (Table 1; and Table S1 in the Sup-
plementary Appendix, available at NEJM.org). 
The median age was 54 years. In 95.8% of the 
patients, the primary tumor was 5 cm or small-
er, and 87.5% of the patients had either no in-
volved axillary nodes or one to three involved 
axillary nodes. Details regarding axillary sur-
gery are summarized in Table S2 in the Supple-
mentary Appendix.
Treatment
A total of 76.1% of the patients had breast-con-
serving surgery followed by whole-breast radia-
tion therapy; in 85.1% of these patients, this ra-
diation therapy was followed by boost irradiation 
to the primary tumor bed. After mastectomy, 
73.4% of the patients underwent chest-wall ir-
radiation. A total of 7.4% of the patients in the 
control group and 8.3% of the patients in the 
nodal-irradiation group underwent axillary irra-
diation. The radiation treatment target volume 
consisted of the first three intercostal spaces, up 
to and including the first five intercostal spaces 
in patients with lower inner-quadrant tumors. 
The supraclavicular field laterally reached the 
acromioclavicular joint, the apical axillary clips 
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positioned by the surgeon, or both, thereby in-
cluding the upper part of the axilla.15
Adjuvant systemic therapy was administered 
depending on risk factors, including nodal in-
volvement, tumor size and grade, and patient age. 
Nearly all patients with node-positive disease 
(99.0%) and 66.3% of patients with node-nega-
tive disease received systemic treatment (Table S3 
in the Supplementary Appendix), but the details 
of that treatment were not obtained. A total of 
41 patients who were randomly assigned to the 
control group (2.0%) and 1944 patients who 
were randomly assigned to the nodal-irradiation 
group (97.1%) underwent regional nodal irradia-
Figure 1. Enrollment, Randomization, and Follow-up of the Study Patients.
All 4004 patients who were enrolled underwent randomization. However, a retrospective medical review indicated 
that 32 of these patients had not been eligible. Follow-up status at the clinical cutoff date of the final analysis is shown. 
The analysis of long-term side effects included eligible patients who received the assigned treatment.
4004 Underwent randomization
4004 Patients were enrolled
32 Were not eligible
16 Had concurrent disease
6 Had lesion in external quadrants
3 Had stage T4 tumors
3 Had metastases
1 Had stage N3 lymph nodes
3 Had other reasons (adenoid cystic carcinoma,
contralateral breast cancer, breast anatomy
that made locoregional irradiation impossible)
2002 Were assigned to not undergo
regional nodal irradiation
2002 Were assigned to undergo
regional nodal irradiation
69 Did not receive treatment
per protocol
56 Received no regional irra-
diation (6 were ineligible)
8 Received partial regional
irradiation
3 Received ≤20 Gy regional
irradiation
2 Did not have treatment
data on case-report form
45 Did not receive treatment
per protocol
20 Received regional irra-
diation (1 was ineligible)
21 Received partial regional
irradiation
4 Did not have treatment
data on case-report form
(1 was ineligible)
2002 Were included in follow-up
1452 Were alive
121 Were lost to follow-up
429 Died (310 from breast cancer)
468 Had breast-cancer events (local
 or regional recurrence, distant 
progression, death from breast
cancer, new ipsilateral breast cancer)
2002 Were included in follow-up
1501 Were alive
119 Were lost to follow-up
382 Died (259 from breast cancer)
407 Had breast-cancer events (local
or regional recurrence, distant 
progression, death from breast
cancer, new ipsilateral breast cancer)
2002 Were included in intention-to-treat
analysis
1944 Were included in analysis of long-term
side effects
2002 Were included in intention-to-treat
analysis
1922 Were included in analysis of long-term
side effects
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tion (1936 patients underwent regional irradiation 
and 8 patients underwent partial regional irra-
diation).
Long-Term Side Effects
In the 3866 eligible patients who received the 
assigned treatment, toxic effects were evaluated 
at all follow-up visits before disease progression 
or the development of a new primary cancer. 
This evaluation showed that after 10 years of 
follow-up, 3% of the patients had pulmonary 
fibrosis (4.4% in the nodal-irradiation group vs. 
1.7% in the control group, P<0.001), 1% had 
cardiac fibrosis (1.2% vs. 0.6%, P = 0.06), and 6% 
had cardiac disease (6.5% vs. 5.6%, P = 0.25). No 
significant difference was observed between the 
two study groups with respect to other late toxic 
effects or performance status. As compared with 
the previous 3-year morbidity report,17 we found 
an increase in the risk of pulmonary fibrosis 
(from 0.9% to 1.7% in the control group and from 
2.8% to 4.4% in the nodal-irradiation group). 
A total of 191 second cancers were diagnosed in 
the nodal-irradiation group and 222 were diag-
nosed in the control group.
Disease-free Survival and Distant Disease-free 
Survival
The type and frequency of events are shown in 
Table 2. At the time of the final analysis, recur-
rence of disease in the regional nodes had devel-
oped in 139 patients, local recurrences had de-
veloped in 219 patients, and distant disease had 
developed in 711 patients. Disease-free survival 
at 10 years was 72.1% (95% confidence interval 
[CI], 70.0 to 74.1) in the nodal-irradiation group 
and 69.1% (95% CI, 66.9 to 71.2) in the control 
group (hazard ratio for disease progression or 
death, 0.89; 95% CI, 0.80 to 1.00; P = 0.04) (Fig. 
S1A in the Supplementary Appendix). Distant 
Characteristic
Control  
Group 
(N = 2002)
 Nodal-Irradiation 
Group  
(N = 2002)
Total  
(N = 4004)
Age — yr
Median 54.0 54.0 54.0
Range 22.0–75.0 19.0–75.0 19.0–75.0
Type of surgery — no. (%)
Mastectomy 479 (23.9) 476 (23.8) 955 (23.9)
Breast-conserving surgery 1523 (76.1) 1526 (76.2) 3049 (76.1)
Pathological tumor stage — no. (%)
pT1: ≤2 cm 1203 (60.1) 1205 (60.2) 2408 (60.1)
pT2: 2–5 cm 714 (35.7) 716 (35.8) 1430 (35.7)
pT3: >5 cm 71 (3.5) 70 (3.5) 141 (3.5)
Pathological nodal stage — no. (%)
pN0: no axillary lymph nodes involved 890 (44.5) 888 (44.4) 1778 (44.4)
pN1a: 1–3 axillary lymph nodes involved 866 (43.3) 859 (42.9) 1725 (43.1)
pN2a: 4–9 axillary lymph nodes involved 201 (10.0) 195 (9.7) 396 (9.9)
pN3a: >9 axillary lymph nodes involved 44 (2.2) 59 (2.9) 103 (2.6)
Adjuvant treatment — no. (%)
None 301 (15.0) 324 (16.2) 625 (15.6)
Chemotherapy 500 (25.0) 494 (24.7) 994 (24.8)
Hormonal therapy 599 (29.9) 586 (29.3) 1185 (29.6)
Both chemotherapy and hormonal therapy 602 (30.1) 598 (29.9) 1200 (30.0)
*  The control group received whole-breast or thoracic-wall irradiation alone, as compared with the nodal-irradiation group, 
which received whole-breast or thoracic-wall irradiation in addition to regional nodal irradiation. There were no signifi-
cant differences between the groups.
Table 1. Baseline Characteristics of the Patients, According to Study Group.*
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disease-free survival at 10 years was 78.0% (95% 
CI, 76.1 to 79.8) among patients who underwent 
regional nodal irradiation and 75.0% (95% CI, 
73.0 to 77.0) among patients who did not 
 undergo regional nodal irradiation (P = 0.02) 
(Fig. 2A). The rate of any first recurrence of 
breast cancer at 10 years was 19.4% (95% CI, 
17.6 to 21.1) in the nodal-irradiation group, as 
compared with 22.9% (95% CI, 21.0 to 24.8) in 
the control group (P = 0.02) (Fig. S2 in the Supple-
mentary Appendix). The number needed to treat 
to avoid one relapse of breast cancer was 30.
Overall Survival and Breast-Cancer 
Mortality
In total, 382 patients who underwent regional 
nodal irradiation and 429 patients who did not 
undergo regional nodal irradiation died. In both 
groups, the main cause of death was breast can-
cer (259 patients in the nodal-irradiation group 
and 310 patients in the control group). Overall 
survival at 10 years was 82.3% (95% CI, 80.4 to 
83.9) among patients who underwent regional 
nodal irradiation and 80.7% (95% CI, 78.8 to 82.5) 
among patients who did not undergo regional 
nodal irradiation (P = 0.06) (Fig. 2B). The benefit 
with respect to overall survival remained border-
line significant with simultaneous adjustment 
for the stratification factors (P = 0.05).
At 10 years, the rate of death from breast 
cancer was 12.5% (95% CI, 11.0 to 14.0) among 
patients in the nodal-irradiation group and 14.4% 
(95% CI, 12.8 to 16.0) among patients in the 
control group (P = 0.02) (hazard ratio, 0.82; 95% 
CI, 0.70 to 0.97; P = 0.02). The number needed to 
treat to avoid one death from breast cancer was 
39 for the entire patient population. Data are 
provided in Figure S1B in the Supplementary Ap-
pendix.
Risk Groups
The treatment effect on all end points was inde-
pendent of all stratification factors (P>0.10) 
(Fig. 3, and Fig. S3 in the Supplementary Appen-
dix). We found a slightly more pronounced ben-
efit of regional nodal irradiation with respect to 
overall survival when both chemotherapy and 
hormonal therapy were administered as adjuvant 
systemic therapy (hazard ratio for death, 0.72; 
95% CI, 0.55 to 0.94). However, this effect may 
reflect some difference in the biology of hor-
mone receptor–positive tumors, since adjuvant 
therapies were not randomly assigned (Fig. S4 in 
the Supplementary Appendix).
Discussion
At a median follow-up of 10.9 years, our study 
showed that irradiation of the internal mam-
mary and medial supraclavicular lymph nodes 
(regional nodal irradiation) was associated with 
a small but significant benefit with respect to 
Event
Control  
Group 
(N = 2002)
Nodal-Irradiation 
Group  
(N = 2002)
Total  
(N=4004)
no. of patients (%)
Recurrence
Local 107 (5.3) 112 (5.6) 219 (5.5)
Regional* 85 (4.2) 54 (2.7) 139 (3.5)
Axillary 38 (1.9) 27 (1.3) 65 (1.6)
Medial supraclavicular 41 (2.0) 30 (1.5) 71 (1.8)
Internal mammary 16 (0.8) 4 (0.2) 20 (0.5)
Distant disease 392 (19.6) 319 (15.9) 711 (17.8)
Second cancer
Any 222 (11.1) 191 (9.5) 413 (10.3)
Ipsilateral or contralateral breast cancer 105 (5.2) 97 (4.8) 202 (5.0)
*  Multiple locations of regional recurrence may have been observed.
Table 2. Events in the Intention-to-Treat Population.
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the rates of disease-free survival, distant disease-
free survival, and death from breast cancer. 
Overall survival at 10 years exceeded 80%, and 
the main cause of death remained breast cancer 
(67.8% in the nodal-irradiation group vs. 72.3% 
in the control group). We did not observe sig-
nificant differences between the randomization 
groups with respect to other causes of death. 
Although there was a trend toward improvement 
in the rate of overall survival in the entire patient 
cohort, this could not be confirmed by means of 
the unadjusted log-rank test (hazard ratio for 
death, 0.87; 95% CI, 0.76 to 1.00; P = 0.06).
The recently published meta-analysis of the 
Early Breast Cancer Trialists’ Collaborative Group 
included individual data on 8135 women from 
22 trials who were treated with mastectomy and 
axillary surgery and were randomly assigned to 
undergo or not undergo locoregional irradia-
tion.18 In patients who had involved axillary 
nodes after axillary dissection, locoregional irra-
diation was associated with significantly lower 
Figure 2. Distant Disease-free and Overall Survival.
Kaplan–Meier curves for survival free from distant disease (Panel A) and overall survival (Panel B) are shown.
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Figure 3. Hazard Ratio for Death, According to Subgroups.
O-E indicates the difference between the number of events observed and the number of events expected. The size of the squares is pro-
portional to the size of the subgroups.
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58/336
106/702
79/488
248/1097
122/763
12/142
167/1205
188/716
23/70
105/888
179/859
66/195
32/59
382/2002
(19.1%)
155/823
274/1179
176/681
253/1321
150/479
61/340
142/700
76/483
285/1100
128/760
16/142
185/1203
221/714
21/71
130/890
199/866
77/201
23/44
429/2002
(21.4%)
−8.1
−19.3
−6.3
−20.3
−6.8
−1.1
−19.7
0.5
−20.4
−4.7
−2.2
−9.8
−20.9
0.3
−13.8
−10.8
−6.0
0.0
−27.3
73.7
128.9
84.7
118.0
72.2
29.7
62.0
38.7
133.2
62.5
7.0
88.0
102.1
10.9
58.7
94.5
35.7
13.4
202.7
no. of events/total no.
Treatment effect: P=0.06
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rates of regional and overall recurrences and 
death from breast cancer. This benefit was inde-
pendent of the number of involved axillary 
nodes (the decrease in the rate of any recurrence 
was 11.5% among women with one to three in-
volved axillary nodes vs. 8.8% among women 
with four positive nodes, and the corresponding 
decrease in the rate of death from breast cancer 
was 7.9% vs. 9.3%). In patients with one to three 
involved nodes, the absolute benefit was the same 
with or without systemic therapy. A previous 
Early Breast Cancer Trialists’ Collaborative Group 
meta-analysis, which included individual patient 
data on 10,801 women in 17 randomized trials, 
showed a similar benefit associated with post-
operative irradiation after breast-conserving 
surgery.19
Despite this evidence in favor of postoperative 
irradiation in the multimodal treatment of most 
patients after breast-conserving therapy and for 
all patients with node-positive breast cancer after 
mastectomy, neither the individual randomized 
trials nor the meta-analyses provided valuable 
information on the effect of irradiation of the 
respective nodal target volumes.18,19 The role of 
radiation directed to the internal mammary 
nodes was questioned, particularly since its use 
was associated with radiation-associated cardiac 
death, which was probably attributable to out-
dated radiation techniques.20-29 It remains unde-
fined whether this risk is significantly lowered 
by advances in radiation techniques.
The interpretation of our results is complex 
in the light of current developments, including 
a greater proportion of screen-detected cancers, 
the increasing use of adjuvant systemic therapy, 
and improving radiation-therapy techniques.30,31 
The interaction among prognostic factors, the 
use of systemic therapy, and the benefit of im-
proving regional control has been described 
previously.32 The benefit of regional-node irra-
diation was also seen in patients with medially 
or centrally located primary tumors without axil-
lary nodal involvement.
Our results are similar to those of the Na-
tional Cancer Institute of Canada Clinical Trials 
Group MA.20 trial.33 That study, which involved 
1832 patients with node-positive or high-risk 
node-negative disease after breast-conserving 
therapy, showed that regional nodal irradiation 
was associated with improved disease-free sur-
vival and distant disease-free survival. The results 
of the study by Hennequin et al. showed a lack 
of benefit of regional nodal irradiation; however, 
that study was smaller than our study and the 
patients had a poorer outcome (a 10% lower rate 
of overall survival at the 5-year follow-up and a 
20% lower rate of overall survival at the 10-year 
follow-up).34
We found a low rate of heart disease and 
death from heart disease after 10.9 years of fol-
low-up, as has been reported before.17,34 However, 
Darby et al. found a dose-dependent increased 
risk of late ischemic heart disease associated 
with radiotherapy for cancer of the left breast.28 
Cardiac disease after radiation therapy might 
have onset early after treatment.28 The radiation-
therapy techniques used in our trial, guided by a 
thorough quality-assurance program, minimized 
the radiation dose to the heart, possibly to a 
clinically less relevant level.15 Nevertheless, addi-
tional follow-up is required to assess late cardiac 
complications.
As compared with the previous 3-year mor-
bidity report,17 we found only a slight increase in 
the risk of pulmonary fibrosis. These results are 
consistent with the results of studies of late pul-
monary disease after radiation therapy for breast 
cancer.35-37 The low frequency of lymphedema 
(10.5% in the control group and 12.0% in the 
nodal-irradiation group) is probably due to the 
fact that the operated part of the axilla was not 
irradiated unless adverse risk factors were pres-
ent. Overall, only 7.4% of patients in the control 
group and 8.3% in the nodal-irradiation group 
underwent irradiation to the axilla.
We recognize the limitations of our study, 
which was initiated in the early 1990s to inves-
tigate whether elective regional nodal irradiation 
would improve long-term overall survival.38 Since 
the regional nodes are functionally interconnect-
ed, it was decided to include the medial supra-
clavicular nodes, thereby in fact randomizing 
between complete nodal treatment (axillary sur-
gery and irradiation of nondissected nodes) and 
axillary surgery alone. Therefore, we cannot de-
termine whether internal mammary irradiation 
or medial supraclavicular irradiation contributed 
more to the outcome. However, the recent re-
sults from the Danish population-based study in 
which patients with left-sided node-positive breast 
cancer underwent only medial supraclavicular 
irradiation, whereas patients with right-sided 
node-positive breast cancer underwent both in-
ternal mammary and medial supraclavicular 
irradiation, support the role of including the 
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internal mammary chain in the success of re-
gional nodal radiation therapy.39,40
When our trial was designed, adjuvant sys-
temic therapy was not as variable as it is today 
and molecular subtypes were not yet described; 
thus, we recorded little information about these 
variables (Table S3 in the Supplementary Appen-
dix). In the current study, the number needed to 
treat to avoid one death from breast cancer was 
39, and the number needed to treat to avoid one 
relapse of breast cancer was 30.
In summary, we found that regional nodal 
irradiation was beneficial to women with early-
stage breast cancer. It improved the rates of 
disease-free and distant disease-free survival and 
reduced the rate of death from breast cancer 
among patients with involved axillary nodes, a 
medially or centrally located primary tumor, or 
both. Improvement in the rate of overall survival 
was not confirmed with 10 years of follow-up. 
Acute side effects were modest, and the rate of 
death from causes other than breast cancer was 
not increased. Our data do not apply to patients 
with lateral node-negative cancers, which is the 
largest patient subgroup in industrialized coun-
tries. Post-treatment follow-up for a median of 
20 years is ongoing.
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